Physician profile
Srikanth Damodaram
NPI 1922269299
$9,066.88
in general payments reported to CMS, 2019-2025
45 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.54 · 2020: $156 · 2021: $1,316 · 2022: $1,929 · 2023: $3,257 · 2024: $1,030 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,508 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,507.85 |
| Education | $136.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,427.06 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,127.40 | 2021-2025 | |
| Sk Life Science, INC. | $874.10 | 2021-2025 | |
| Pfizer INC. | $800.97 | 2023-2025 | |
| Ucb, INC. | $524.53 | 2021-2025 | Briviact, Nayzilam, Fintepla |
| Biogen, INC. | $415.80 | 2021-2025 | Vumerity, Tysabri, Tysabri |
| Biohaven Pharmaceutical Holding Company LTD. | $344.99 | 2022 | |
| Neurocrine Biosciences, INC. | $342.60 | 2022-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $256.66 | 2021-2024 | Hyqvia, Gammagard |
| Acadia Pharmaceuticals INC | $245.13 | 2021-2025 | Nuplazid |
| Allergan, INC. | $213.76 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $202.91 | 2022-2023 | Austedo, Austedo Xr, Ajovy |
| Amgen INC. | $195.61 | 2021-2023 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $161.12 | 2020-2021 | |
| Janssen Biotech, INC. | $146.50 | 2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $138.54 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Amneal Pharmaceuticals LLC | $138.09 | 2022-2025 | Rytary, Crexont |
| Abbott Laboratories | $130.79 | 2021-2025 | Infinity |
| Averitas Pharma INC. | $129.15 | 2023-2024 | Qutenza |
| Grifols USA, LLC | $114.89 | 2023 | Gamunex-C |
| Medtronic, INC. | $110.21 | 2023 | Activa PC |
| Lundbeck LLC | $101.15 | 2020-2023 | Rexulti |
| Acorda Therapeutics, INC | $78.47 | 2022-2024 | Inbrija, Ampyra |
| Eisai INC. | $75.29 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $74.04 | 2025 | Dysport |
| Emd Serono, INC. | $70.47 | 2022-2024 | |
| Livanova USA, INC. | $63.77 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ge Healthcare | $54.43 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $49.17 | 2023 | Hetlioz |
| Tg Therapeutics, INC. | $47.15 | 2025 | |
| Genzyme Corporation | $46.72 | 2022 | |
| Painteq LLC | $46.50 | 2023 | Painteq |
| Axsome Therapeutics, INC. | $39.08 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $36.42 | 2020-2021 | |
| Tanabe Pharma America, INC. | $29.32 | 2025 | Radicava |
| Jazz Pharmaceuticals INC. | $29.19 | 2025 | |
| Medtronic USA, INC. | $24.56 | 2020 | |
| Sunovion Pharmaceuticals INC. | $23.36 | 2022 | |
| Avion Pharmaceuticals | $22.92 | 2022 | |
| Celgene Corporation | $22.20 | 2025 | Zeposia |
| Nevro Corp. | $19.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.31 | 2021 | |
| Upsher-Smith Laboratories LLC | $19.17 | 2020 | |
| Octapharma USA, INC. | $16.92 | 2022 | |
| Tonix Medicines, INC. | $16.54 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikanth Damodaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.